Skip to main content

Table 1 Background data for the 75-year old study participants (n = 154).

From: Prevalence of abnormal glucose metabolism in atrial fibrillation: A case control study in 75-year old subjects

 

Atrial fibrillation

No atrial fibriallation

Chi-square/df/p or t/d.f/p

Gender (male/female)

34 (31.8%)/12 (25.5%)

73 (68.2%)/35 (74.5%)

0.608/1/0.44

BMI (kg/m2)

25.3 ± 3.7

25.4 ± 3.2

-0.176/145/0.86

Waist (cm)

93.5 ± 11.7

91.6 ± 10.9

0.936/151/0.35

SBP (mmHg)

143 ± 21

147 ± 16

-1.169/152/0.24

DBP (mmHg)

82 ± 10

81 ± 9

1.069/152/0.29

Concomitant disorders, n (%)

Hypertension

38 (82.6%)

83 (76.9%)

0.635/1/0.43

MI

6 (13.0%)

11 (10.2%)

0.268/1/0.60

HF

7 (15.2)*

0 (0.0%)

< 0.001 (Fisher)

Valve surgery

3 (6.5%)*

1 (0.9%)

0.046 (Fisher)

CABG/PCI

6 (13.0%)

8 (7.4%)

1.240/1/0.27

Cerebrovascular disease

5 (10.9%)*

2 (1.9%)

0.025 (Fisher)

Medication, n (%)

Warfarin

33 (76.1%)*

4 (3.7%)

< 0.001 (Fisher)

Acetylic acid

3 (6.5%)

33 (30.6%)*

0.001 (Fisher)

Digitoxin

8 (17.4)*

0 (0%)

< 0.001 (Fisher)

Verapamil

10 (21.7)*

2 (1.9)

< 0.001 (Fisher)

Other Ca2+ blockers

4 (8.7)

11 (8.7)

1.000 (Fisher)

Beta blockers

14 (30.4%)*

16 (14.8%)

5.018/1/0.03*

ACE inhibitor

12 (26.1%)*

13 (12.0%)

4.683/1/0.03*

AT-II antagonist

13 (28.3%)*

13 (12.0%)

6.051/1/0.01*

Diuretics

12 (26.1%)*

5 (4.6%)

15.125/1/<0.001*

Statins

18 (39.1)*

19 (17.6)

8.198/1/0.01*

Laboratory parameters

Total leukocyte count (109)

6.0 ± 1.3

6.2 ± 1.6

-0.52/140/0.61

Creatinine (μmol/l)

84 ± 21

80 ± 23

0.93/137/0.35

Total cholesterol (mmol/l)

5.2 ± 1.0*

5.6 ± 1.1

-2.326/140/0.02*

Triglycerides (mmol/l)

1.1 ± 0.8

1.1 ± 0.6

0.162/140/0.87

HDL-cholesterol (mmol/l)

1.7 ± 0.6

1.7 ± 0.5

0.443/140/0.66

LDL-cholesterol (mmol/l)

2.9 ± 0.9*

3.4 ± 1.0

-2.713/139/0.01

  1. *: p ≤ 0.05. Abbreviations: BMI – body mass index, SBP – systolic blood pressure, DBP – diastolic blood pressure, MI – myocardial infarction, HF – heart failure, CABG – coronary artery by-pass graft, PCI – percutaneous coronary intervention, Ca2+-calcium, ACE – angiotensin converting enzyme, AT-II – angiotensin II, HDL – high density lipoprotein, LDL – low density lipoprotein.